Sarepta Therapeutics (SRPT) Sees Wild Late-Day Action
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Wedbush Sees Sarepta Therapeutics (SRPT) Filing for Accelerated Approval of Eteplirsen
April 15, 2013 1:06 PM EDTWedbush reiterated its Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following two presentations at the World Orphan Drug Congress last week. Insight from the Congress suggests an accelerated approval filing of eteplirsen is likely, analysts led by Christopher N. Marai, Ph.D said.
"SRPT's main presentation focused on the potential regulatory path forward for follow-on compounds to treat DMD caused by mutations in rarer exons where running trials could be impractical," the Marai-led group... More
